Cannabidiol is without a doubt the breakout star among medicines this decade, if not the century. The cannabis extract is a darling of the medicine, sports, and the health and wellness communities, with potent and versatile medicinal properties that make it effective against a wide range of diseases. A lot of people use it for pain and anxiety relief, but anecdotally, CBD has worked against high blood pressure, improved sleep and reduced seizures in people with epilepsy. In June 2018, the FDA approved a CBD-based medication to help manage seizures in rare forms of childhood epilepsy.
Recently the UK National Health Service (NHS) approved the use of two CBD-based drugs for use in the United Kingdom, Epidiolex and Sativex. Sativex is a mouth spray used to treat multiple sclerosis-related muscle stiffness and spasms. Epidyolex, on the other hand, was approved for use by children with two rare and hard to manage forms of epilepsy, Dravet syndrome, and Lennox Gastaut syndrome. Geraldine Woodman is one of the people who were…
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
[email protected]
CBDWire is part of the InvestorBrandNetwork.